Have Your Say - PBAC Call for Consumer Comments |
The Australian Government Pharmaceutical Benefits Advisory Committee (PBAC) has invited consumers to comment on an application for subsidisation of the medicine ERLYAND, also known as apalutamide, and what it may mean for men living with prostate cancer.
The application is seeking Pharmaceutical Benefits Scheme (PBS) subsidisation specifically for the treatment of patients with high-risk castration-resistant prostate cancer with no distant metastases, which is defined by PSA doubling time of less than about 10 months.
PBAC would like to hear from Australian men living with this particular stage of prostate cancer, their carers, and family members to help inform their decision on whether to subsidise the drug.
PCFA, through its Prostate Cancer Support Group Network, is gathering comments via an open form survey to send to PBAC – exactly as provided – on behalf of Network consumers.
The application is seeking Pharmaceutical Benefits Scheme (PBS) subsidisation specifically for the treatment of patients with high-risk castration-resistant prostate cancer with no distant metastases, which is defined by PSA doubling time of less than about 10 months.
PBAC would like to hear from Australian men living with this particular stage of prostate cancer, their carers, and family members to help inform their decision on whether to subsidise the drug.
PCFA, through its Prostate Cancer Support Group Network, is gathering comments via an open form survey to send to PBAC – exactly as provided – on behalf of Network consumers.